Free Trial

Heatwurx (PCSA) Competitors

Heatwurx logo
$0.30 -0.02 (-5.84%)
Closing price 10/21/2025 04:00 PM Eastern
Extended Trading
$0.26 -0.04 (-13.97%)
As of 07:38 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PCSA vs. ALGS, CUE, GNTA, ANL, MNOV, OTLK, ELYM, ACRV, SNTI, and JATT

Should you be buying Heatwurx stock or one of its competitors? The main competitors of Heatwurx include Aligos Therapeutics (ALGS), Cue Biopharma (CUE), Genenta Science (GNTA), Adlai Nortye (ANL), MediciNova (MNOV), Oncobiologics (OTLK), Eliem Therapeutics (ELYM), Acrivon Therapeutics (ACRV), Senti Biosciences (SNTI), and JATT Acquisition (JATT). These companies are all part of the "pharmaceutical products" industry.

Heatwurx vs. Its Competitors

Aligos Therapeutics (NASDAQ:ALGS) and Heatwurx (NASDAQ:PCSA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Heatwurx has lower revenue, but higher earnings than Aligos Therapeutics. Aligos Therapeutics is trading at a lower price-to-earnings ratio than Heatwurx, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aligos Therapeutics$3.94M16.37-$131.21M-$19.79-0.53
HeatwurxN/AN/A-$11.85M-$2.32-0.13

Heatwurx has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -2,337.24%. Aligos Therapeutics' return on equity of -22.41% beat Heatwurx's return on equity.

Company Net Margins Return on Equity Return on Assets
Aligos Therapeutics-2,337.24% -22.41% -12.09%
Heatwurx N/A -342.36%-243.48%

60.4% of Aligos Therapeutics shares are held by institutional investors. Comparatively, 91.9% of Heatwurx shares are held by institutional investors. 4.8% of Aligos Therapeutics shares are held by company insiders. Comparatively, 2.4% of Heatwurx shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Aligos Therapeutics presently has a consensus price target of $50.00, suggesting a potential upside of 376.64%. Heatwurx has a consensus price target of $1.00, suggesting a potential upside of 233.44%. Given Aligos Therapeutics' higher possible upside, equities analysts plainly believe Aligos Therapeutics is more favorable than Heatwurx.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aligos Therapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Heatwurx
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Aligos Therapeutics had 2 more articles in the media than Heatwurx. MarketBeat recorded 3 mentions for Aligos Therapeutics and 1 mentions for Heatwurx. Aligos Therapeutics' average media sentiment score of 0.24 beat Heatwurx's score of -1.00 indicating that Aligos Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Aligos Therapeutics Neutral
Heatwurx Negative

Aligos Therapeutics has a beta of 2.77, suggesting that its stock price is 177% more volatile than the S&P 500. Comparatively, Heatwurx has a beta of 1.53, suggesting that its stock price is 53% more volatile than the S&P 500.

Summary

Aligos Therapeutics beats Heatwurx on 8 of the 13 factors compared between the two stocks.

Get Heatwurx News Delivered to You Automatically

Sign up to receive the latest news and ratings for PCSA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PCSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PCSA vs. The Competition

MetricHeatwurxMED IndustryMedical SectorNASDAQ Exchange
Market Cap$16.04M$3.01B$6.22B$10.67B
Dividend YieldN/A57.78%5.74%4.88%
P/E Ratio-0.1323.5929.1427.23
Price / SalesN/A786.13589.44132.72
Price / CashN/A171.3937.5161.65
Price / Book0.655.4112.566.59
Net Income-$11.85M$33.06M$3.32B$276.14M
7 Day Performance-26.82%-0.68%0.73%-0.72%
1 Month Performance51.77%8.13%7.29%2.47%
1 Year Performance-77.62%-2.15%65.05%33.90%

Heatwurx Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PCSA
Heatwurx
2.4699 of 5 stars
$0.30
-5.8%
$1.00
+233.4%
-78.7%$16.04MN/A-0.1320Negative News
Upcoming Earnings
Short Interest ↑
Gap Down
ALGS
Aligos Therapeutics
3.9202 of 5 stars
$10.44
+4.5%
$50.00
+378.9%
+43.9%$61.45M$3.94M-0.5390
CUE
Cue Biopharma
2.2262 of 5 stars
$0.82
+3.1%
N/A-50.9%$61.19M$9.29M-1.4760
GNTA
Genenta Science
N/A$3.20
+0.6%
N/A-38.5%$60.82MN/A0.007
ANL
Adlai Nortye
1.2619 of 5 stars
$1.65
+0.6%
$9.00
+445.5%
-15.1%$60.52M$5M0.00127News Coverage
Short Interest ↑
Gap Up
MNOV
MediciNova
1.7784 of 5 stars
$1.21
-1.6%
$7.00
+478.5%
-31.5%$60.33M$134.60K-4.8410
OTLK
Oncobiologics
2.8089 of 5 stars
$1.48
+13.0%
$7.00
+373.0%
-75.2%$58.19MN/A-2.6020Positive News
Gap Down
ELYM
Eliem Therapeutics
N/A$1.93
-1.0%
N/A-53.8%$57.42MN/A-3.649Gap Up
ACRV
Acrivon Therapeutics
2.3547 of 5 stars
$1.92
+6.1%
$15.00
+681.3%
-74.7%$56.94MN/A-0.8558News Coverage
SNTI
Senti Biosciences
3.4029 of 5 stars
$2.14
-0.5%
$9.67
+351.7%
-9.3%$56.24MN/A-0.244
JATT
JATT Acquisition
N/A$3.21
-6.4%
N/A-31.5%$55.37MN/A0.003High Trading Volume

Related Companies and Tools


This page (NASDAQ:PCSA) was last updated on 10/22/2025 by MarketBeat.com Staff
From Our Partners